Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GST-HG171 + ritonavir for mild to moderate COVID-19
ChiCTR2200067088Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atilotrelvir and ritonavir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Time to sustained clinical recovery of 11 COVID-19 symptoms. Started Dec 2022; status: recruiting.
02
Drugs
atilotrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200067088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067088.